Marvel Biosciences Corp (TSE:MRVL) has released an update.
Marvel Biosciences Corp. has successfully completed a private placement, raising $500,000 through the issuance of 5 million units at $0.10 each. These funds are earmarked for further pre-clinical research on Alzheimer’s and Autism as well as for general corporate purposes. The units, which include common shares and purchase warrants, are subject to a four-month hold period and the approval of the TSX Venture Exchange.
For further insights into TSE:MRVL stock, check out TipRanks’ Stock Analysis page.
